Pathways to motor incoordination: The inherited ataxias

Nature Reviews Neuroscience

Volumn 5, Issue 8, 2004, Pages 641-655

  Taroni, Franco ^a   DiDonato, Stefano ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIA; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; CELL DEATH; GENE INACTIVATION; GENE MUTATION; HEREDITARY ATAXIA; HUMAN; MOTOR COORDINATION; NERVE CELL LESION; NERVE DEGENERATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SPINOCEREBELLAR DEGENERATION;

ATAXIA;

EID: 3543031667     PISSN: 1471003X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrn1474     Document Type: Review

References (148)

1. Orr, H. T. et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nature Genet. 4, 221-226 (1993). Cloning of a highly polymorphic CAG repeat in the SCA1 gene on chromosome 6 and demonstration that the trinucleotide repeat is transcribed and shows prominent expansion in heterozygosity that segregates in affected individuals.
2. Stevanin, G. et al. Spinocerebellar ataxia with sensory neuropathy (SCA25) maps to chromosome 2p. Ann. Neurol. 55, 97-104 (2004).
3. DiDonato, S., Gellera, C. & Mariotti, C. The complex clinical and genetic classification of inherited ataxias. II. Autosomal recessive ataxias. Neurol. Sci. 22, 219-228 (2001).
4. Zoghbi, H. Y. & Orr, H. T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
5. Ross, C. A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35, 819-822 (2002).
6. Zoghbi, H. Y. & Botas, J. Mouse and fly models of neurodegeneration. Trends Genet. 18, 463-471 (2002).
7. DiDonato, S. Disorders related to mitochondrial membranes: pathology of the respiratory chain and neurodegeneration. J. Inher. Metab. Dis. 23, 247-263 (2000).
8. Lopez-Arlandis, J. M., Vilchez, J. J., Palau, F. & Sevilla, T. Friedreich's ataxia: an epidemiological study in Valencia, Spain, based on consanguinity analysis. Neuroepidemiology 14, 14-19 (1995).
9. Cossee, M. et al. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc. Natl Acad. Sci. USA 94, 7452-7457 (1997).
10. Lamarche, J. B., Lemieux, B. & Lieu, H. B. The neuropathology of 'typical' Friedreich's ataxia in Quebec. Can. J. Neurol. Sci. 11, 592-600 (1984).
11. Koeppen, A. H. The hereditary ataxias. J. Neuropathol. Exp. Neurol. 57, 531-543 (1998).
12. Campuzano, V. et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427 (1996). Cloning of the Friedreich ataxia gene and identification of a novel genetic mechanism of disease consisting of the expansion of a GAA triplet in an intron of a recessive gene.
13. Dürr, A. et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335, 1169-1175 (1996).
14. Montermini, L. et al. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum. Mol. Genet. 6, 1261-1266 (1997).
15. Cossee, M. et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann. Neurol. 45, 200-206 (1999).
16. Filla, A. et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am. J. Hum. Genet. 59, 554-560 (1996).
17. Montermini, L. et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann. Neurol. 41, 675-682 (1997).
18. Ohshima, K., Montermini, L., Wells, R. D. & Pandolfo, M. Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J. Biol. Chem. 273, 14588-14595 (1998).
19. Sakamoto, N., Ohshima, K., Montermini, L., Pandolfo, M. & Wells, R. D. Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J. Biol. Chem. 276, 27171-27177 (2001).
20. Cavadini, P., Gellera, C., Patel, P. I. & Isaya, G. Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum. Mol. Genet. 9, 2523-2530 (2000).
21. Campuzano, V. et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6, 1771-1780 (1997).
22. Wong, A. et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8, 425-430 (1999).
23. Branda, S. S. et al. Yeast and human frataxin are processed to mature form in two sequential steps by the mitochondrial processing peptidase. J. Biol. Chem. 274, 22763-22769 (1999).
24. Babcock, M. et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276, 1709-1712 (1997).
25. Adamec, J. et al. Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am. J. Hum. Genet. 67, 549-562 (2000).
26. Gakh, O. et al. Physical evidence that yeast frataxin is an iron storage protein. Biochemistry 41, 6798-6804 (2002).
27. Chantrel-Groussard, K. et al. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum. Mol. Genet. 10, 2061-2067 (2001).
28. Shoichet, S. A. et al. Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in diminished malignant transformation in vitro. Hum. Mol. Genet. 11, 815-821 (2002).
29. Ristow, M. et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc. Natl Acad. Sci. USA 97, 12239-12243 (2000).
30. Rötig, A. et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature Genet. 17, 215-217 (1997).
31. Huynen, M. A., Snel, B., Bork, P. & Gibson, T. J. The phylogenetic distribution of frataxin indicates a role in iron-sulfur cluster protein assembly. Hum. Mol. Genet. 10, 2463-2468 (2001).
32. Tan, G., Napoli, E., Taroni, F. & Cortopassi, G. Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum. Mol. Genet. 12, 1699-1711 (2003). Gene expression analysis of frataxin-deficient cells showing a specific decrease in transcripts of genes involved in sulphur amino-acid metabolism and Fe-S cluster biosynthesis.
33. Foury, F. & Cazzalini, O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. 411, 373-377 (1997).
34. Cavadini, P., O'Neill, H. A., Benada, O. & Isaya, G. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum. Mol. Genet. 11, 217-227 (2002).
35. Adinolfi, S., Trifuoggi, M., Politou, A. S., Martin, S. & Pastore, A. A structural approach to understanding the iron-binding properties of phylogenetically different frataxins. Hum. Mol. Genet. 11, 1865-1877 (2002).
36. Levi, S. et al. A human mitochondrial ferritin encoded by an intronless gene. J. Biol. Chem. 276, 24437-24440 (2001).
37. Lodi, R. et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl Acad. Sci. USA 96, 11492-11495 (1999).
38. Cossée, M. et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 9, 1219-1226 (2000).
39. Puccio, H. et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nature Genet. 27, 181-186 (2001). Conditional mouse models for Friedreich ataxia that recapitulate pathology and biochemical abnormalities present in the human disease.
40. Simon, D. et al. Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J. Neurosci. 24, 1987-1995 (2004).
41. Mühlenhoff, U. & Lill, R. Biogenesis of iron-sulfur proteins in eukaryotes: a novel task of mitochondria that is inherited from bacteria. Biochim. Biophys. Acta 1459, 370-382 (2000).
42. Schilke, B., Voisine, C., Beinert, H. & Craig, E. Evidence for a conserved system for iron metabolism in the mitochondria of Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 96, 10206-10211 (1999).
43. Chen, O. S., Hemenway, S. & Kaplan, J. Inhibition of Fe-S cluster biosynthesis decreases mitochondrial iron export: evidence that Yfh1p affects Fe-S cluster synthesis. Proc. Natl Acad. Sci. USA 99, 12321-12326 (2002).
44. Kispal, G., Csere, P., Prohl, C. & Lill, R. The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins. EMBO J. 18, 3981-3989 (1999).
45. Allikmets, R. et al. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum. Mol. Genet. 8, 743-749 (1999).
46. Mühlenhoff, U., Richhardt, N., Ristow, M., Kispal, G. & Lill, R. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum. Mol. Genet. 11, 2025-2036 (2002).
47. Gerber, J., Muhlenhoff, U. & Lill, R. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep. 4, 906-911 (2003). One of the most convincing demonstrations that frataxin is involved in the biogenesis of Fe-S clusters by showing its specific interaction with a protein that is crucial in the early steps of Fe-S centre biosynthesis.
48. Mühlenhoff, U., Gerber, J., Richhardt, N. & Lill, R. Components involved in assembly and dislocation of iron-sulfur clusters on the scaffold protein Isu1p. EMBO J. 22, 4815-4825 (2003).
49. Ramazzotti, A., Vanmansart, V. & Foury, F. Mitochondrial functional interactions between frataxin and Isu1p, the iron-sulfur cluster scaffold protein, in Saccharomyces cerevisiae. FEBS Lett. 557, 215-220 (2004).
50. Puccio, H. & Koenig, M. Friedreich ataxia: a paradigm for mitochondrial diseases. Curr. Opin. Genet. Dev. 12, 272-277 (2002).
51. Cavalier, L. et al. Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. Am. J. Hum. Genet. 62, 301-310 (1998).
52. DiDonato, S. Can we avoid AVED? Nature Genet. 9, 106-107 (1995).
53. Ouahchi, K. et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the α-tocopherol transfer protein. Nature Genet. 9, 141-145 (1995).
54. Kayden, H. J. The neurologic syndrome of vitamin E deficiency: a significant cause of ataxia. Neurology 43, 2167-2169 (1993).
55. Yokota T et al. Delayed-onset ataxia in mice lacking α-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. Proc. Natl Acad. Sci. USA 98, 15185-15190 (2001).
56. Conner, K. & Rosenberg, R. in The Molecular and Genetic Basis of Neurological Disease (eds Rosenberg, R., Prusiner, S., DiMauro, S. & Barchi, R.) 504-506 (Butterworth-Heinemann, Boston, 1997).
57. Sharp, D. et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinemia. Nature 365, 65-69 (1993).
58. Nystuen, A., Benke, P. J., Merren, J., Stone, E. M. & Sheffield, V. C. A cerebellar ataxia locus identified by DNA pooling to search for linkage disequilibrium in an isolated population from the Cayman Islands. Hum. Mol. Genet. 5, 525-531 (1996).
59. Bomar, J. M. et al. Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse. Nature Genet. 35, 264-269 (2003).
60. Rolig, R. L. & McKinnon, P. J. Linking DNA damage and neurodegeneration. Trends Neurosci. 23, 417-424 (2000).
61. van Gent, D. C., Hoeijmakers, J. H. & Kanaar, R. Chromosomal stability and the DNA double-stranded break connection. Nature Rev. Genet. 2, 196-206 (2001).
62. Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. Nature Rev. Cancer 3, 155-168 (2003). One of the most recent and accurate reviews of the complex and still not completely unravelled cellular function of the AT protein.
63. Caldecott, K. W. DNA single-strand break repair and spinocerebellar ataxia. Cell 112, 7-10 (2003). The first seminal review on the relationships between the SSBR machinery and hereditary neurodegenerative disorders that are primarily characterized by SCA.
64. Swift, M. et al. The incidence and gene frequency of ataxia- telangiectasia in the United States. Am. J. Hum. Genet. 39, 573-583 (1986).
65. Meyn, M. S. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin. Genet. 55, 289-304 (1999).
66. Conner, K. & Rosenberg, R. in The Molecular and Genetic Basis of Neurological Disease (eds Rosenberg, R., Prusiner, S., DiMauro, S. & Barchi, R.) 523-525 (Butterworth-Heinemann, Boston, 1997).
67. Rotman, G. & Shiloh, Y. ATM: from gene to function. Hum. Mol. Genet. 7, 1555-1563 (1998).
68. Laposa, R. R., Henderson, J. T., Xu, E. & Wells, P. G. Atm-null mice exhibit enhanced radiation-induced birth defects and a hybrid form of embryonic cell death indicating a teratological suppressor function for ATM. FASEB J. 18, 896-898 (2004).
69. Bakkenist, C. J. & Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003). An outstanding contribution that highlights the crucial role of ATM in the cellular response to DNA damage through the demonstration that it initiates the repair cascade by autophosphorylation.
70. Sluss, H. K., Armata, H., Gallant, J., Jones, S. N. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol. Cell. Biol. 24, 976-984 (2004).
71. Uziel, T. et al. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J. 22, 5612-5621 (2003).
72. Stewart, G. S. et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 99, 577-587 (1999).
73. Carney, J. P. et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93, 477-486 (1998).
74. Herzog, K. H., Chong, M. J., Kapsetaki, M., Morgan, J. I. & McKinnon, P. J. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 280, 1089-1091 (1998).
75. Stern, N. et al. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of Atm-deficient mice. J. Biol. Chem. 277, 602-608 (2002).
76. Meira, L. B. et al. Heterozygosity for the mouse Apex gene results in phenotypes associated with oxidative stress. Cancer Res. 61, 5552-5557 (2001).
77. Barlow, C. et al. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc. Natl Acad. Sci. USA 96, 9915-9919 (1999).
78. Aicardi, J. et al. Ataxia-ocular motor apraxia: a syndrome mimicking ataxia-teleangiectasia. Ann. Neurol. 24, 497-502 (1988).
79. Hannan, M. A., Sigut, D., Waghray, M. & Gascon, G. G. Ataxia-ocular motor apraxia syndrome: an investigation of cellular radiosensitivity of patients and their families. J. Med. Genet. 31, 953-956 (1994).
80. Date, H. et al. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nature Genet. 29, 184-188 (2001).
81. Moreira, M. C. et al. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nature Genet. 29, 189-193 (2001).
82. Jilani, A. et al. Molecular cloning of the human gene, PNKP, encoding a polynucleotide kinase 3′-phosphatase and evidence for its role in repair of DNA strand breaks caused by oxidative damage. J. Biol. Chem. 274, 24176-24186 (1999).
83. Brenner, C., Bleganowski, P., Pace, H. C. & Huebner, K. The histidine triad superfamily of nucleotide-binding proteins. J. Cell. Physiol. 181, 179-187 (1999).
84. Sano, Y. et al. Aprataxin, the causative protein for EAOH is a nuclear protein with a potential role as a DNA repair protein. Ann. Neurol. 55, 241-249 (2004).
85. Whitehouse, C. J. et al. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell 104, 107-117 (2001).
86. Gueven, N. et al. Aprataxin, a novel protein that protects against genotoxic stress. Hum. Mol. Genet. 13, 1081-1093 (2004). An extensive biochemical study that provides convincing evidence that aprataxin is primarily involved in the cellular response to diverse genotoxic events.
87. Bomont, P. et al. Homozygosity mapping of spinocerebellar ataxia with cerebellar atrophy and peripheral neuropathy to 9q33-34, and with hearing impairment and optic atrophy to 6p21-23. Eur. J. Hum. Genet. 8, 986-990 (2000).
88. Nemeth, A. H. et al. Autosomal recessive cerebellar ataxia with oculomotor apraxia (ataxia-telangiectasia-like syndrome) is linked to chromosome 9q34. Am. J. Hum. Genet. 67, 1320-1326 (2000).
89. Moreira, M. C. et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nature Genet. 36, 225-227 (2004).
90. Kim, H. D., Choe, J. & Seo, Y. S. The sen1 + gene of Schizosaccharomyces pombe, a homologue of budding yeast SEN1, encodes an RNA and DNA helicase. Biochemistry 38, 14697-14710 (1999).
91. Wang, W., Czaplinski, K., Rao, Y. & Peltz, S. W. The role of Upf proteins in modulating the translation read-through of nonsense-containing transcripts. EMBO J. 20, 880-890 (2001).
92. Grohmann, K. et al. Mutations in the gene encoding immunoglobulin μ-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nature Genet. 29, 75-77 (2001).
93. Takashima, H. et al. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nature Genet. 32, 267-272 (2002).
94. Brusco, A. et al. Molecular genetics of hereditary spinocerebellar ataxia. Mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. Arch. Neurol. 61, 727-733 (2004).
95. Robitaille, Y., Schut, L. & Kish, S. J. Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype. Acta Neuropathol. Berl. 90, 572-581 (1995).
96. Durr, A. et al. Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families. Brain 118, 1573-1581 (1995).
97. Durr, A. et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann. Neurol. 39, 490-499 (1996).
98. Gomez, C. M. et al. Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. Ann. Neurol. 42, 933-950 (1997).
99. Gouw, L. G., Digre, K. B., Harris, C. P., Haines, J. H. & Ptacek, L. J. Autosomal dominant cerebellar ataxia with retinal degeneration: clinical, neuropathologic, and genetic analysis of a large kindred. Neurology 44, 1441-1447 (1994).
100. Rolfs, A. et al. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann. Neurol. 54, 367-375 (2003).
101. Takahashi, H. et al. Hereditary dentatorubral-pallidoluysian atrophy: clinical and pathologic variants in a family. Neurology 38, 1065-1070 (1988).
102. Ikeda, H. et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nature Genet. 13, 196-202 (1996).
103. Burright, E. N. et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948 (1995). Generation of the first mice to bear full-length ataxin-1 with an expanded allele of 82 glutamine residues. The mice show loose motor coordination and extensive Purkinje cell loss. It was the first animal model for polyglutamine disorders.
104. Ordway, J. M. et al. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 91, 753-763 (1997).
105. Perutz, M. F. Glutamine repeats and inherited neurodegenerative disease: molecular aspects. Curr. Opin. Struct. Biol. 6, 848-858 (1996). A full theoretical model for conformational change of polyglutamine stretches of 40 or more repeats from α-coiled to pleated β-sheets linked by hydrogen bonds between both their main-chain and side-chain amides, leading, through their adesive properties, to aggregate formation and neurodegeneration.
106. La Spada, A. R. & Taylor, J. P. Polyglutamines placed into context. Neuron 38, 681-684 (2003).
107. Lorenzetti, D. et al. Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus. Hum. Mol. Genet. 9, 779-785 (2000).
108. Yoo, S. Y. et al. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37, 383-401 (2003).
109. Scheel, H., Tomiuk, S. & Hofmann, K. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum. Mol. Genet. 12, 2845-2852 (2003).
110. Chen, H. K. et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113, 457-468 (2003). The demonstration that 14-3-3 protein binds to and stabilizes ataxin-1, mediating its intrinsic neurotoxicity after phosphorylation of Ser-776 of ataxin-1 by the PI3K Akt. This work underscores the importance of the protein context in polyQ-mediated neurodegeneration.
111. Chai, Y., Shoesmith Berke, S., Cohen, R. E., & Paulson H. L. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J. Biol. Chem. 279, 3605-3611 (2004). In stably transfected cell lines, normal and expanded ataxin-3 firmly binds through its UIMs to polyubiquitylated, but not mono- or di-ubiquitylated proteins, showing that ataxin-3 has a specific function that is linked to the protein surveillance machinery.
112. Huynh, D. P., Figueroa, K., Hoang, N. & Pulst, S. M. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nature Genet. 26, 44-50 (2000).
113. Ishikawa, K. et al. Abundant expression and cytoplasmic aggregations of 1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6. Hum. Mol. Genet. 8, 1185-1193 (1999).
114. Sisodia, S. S. Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? Cell 95, 1-4 (1998).
115. Warrick, J. M. et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nature Genet. 23, 425-428 (1999). In an elegant model of neurodegeneration in D. melanogaster obtained through the expression of a truncated C-terminal fragment of ataxin-3 containing 78 Gln repeats, cell pathology and phenotype are rescued by the overexpression of the molecular chaperone Hsp70.
116. Chai, Y., Koppenhafer, S. L., Shoesmith, S. J., Perez, M. K. & Paulson, H. L. Evidence for proteasome involvement in polyglutamine disease: Localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet. 8, 673-682 (1999).
117. Schmidt, T. et al. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann. Neurol. 51, 302-310 (2002).
118. McCampbell, A. et al. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9, 2197-2202 (2000).
119. Berke, S. J. & Paulson, H. L. Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr. Opin. Genet. Dev. 13, 253-261 (2003).
120. Yvert, G. et al. SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. Hum. Mol. Genet. 10, 1679-1692 (2001).
121. Shimohata, T., et al. Expanded polyglutamine stretches interact with TAFII130. Interfering with CREB-dependent transcripton. Nature Genet. 26, 29-35 (2000).
122. Cummings, C. J. et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature Genet. 19, 148-154 (1998).
123. Klement, I. A. et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53 (1998).
124. Emamian, E. S. et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38, 375-387 (2003).
125. Sanchez, I., Mahlke, C. & Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379 (2003).
126. Matilla, A. et al. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 389, 974-978 (1997).
127. Lin, X., Antalffy, B., Kang, D., Orr, H. T. & Zoghbi, H. Y. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nature Neurosci. 3, 157-163 (2000).
128. Fernandez-Funez, P. et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408, 101-106 (2000).
129. Paulson, H. L. et al. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann. Neurol. 41, 453-462 (1997).
130. Kaytor, M. D. et al. Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7. Hum. Mol. Genet. 8, 1657-1664 (1999).
131. Schmidt, T. et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 8, 669-679 (1998).
132. Nucifora, F. C. Jr et al. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J. Biol. Chem. 278, 13047-13055 (2003).
133. Warrick J. M. et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93, 939-949 (1998).
134. Bonini, N. M. Chaperoning brain degeneration. Proc. Natl Acad. Sci. USA 99 (Suppl. 4), 16407-16411 (2002).
135. Evert, B. O. et al. High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Hum. Mol. Genet. 8, 1169-1176 (1999).
136. Donaldson, K. M. et al.. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc. Natl Acad. Sci. USA 100, 8892-8897 (2003).
137. Wang, G. H., Sawai, N., Kotliarova, S., Kanazawa, I. & Nukina, N. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA reapair protein RAD23, HHR23A and HHR23B. Hum. Mol. Genet. 9, 1795-1803 (2000).
138. Chen, L. & Madura, K. Rad23 promotes targeting of proteolytic substrates to the proteasome. Mol. Cell. Biol. 22, 4902-4913 (2002).
139. Doss-Pepe, E. W., Stenroos, E. S., Johnson, W. G., & Madura, K. Ataxin-3 interactions with Rad23 and valosin-containing protein and its association with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol. Cell. Biol. 23, 6469-6483 (2003). Demonstration that ataxin-3 interacts with both ubiquitinated proteins and the proteasome-binding factors Rad23 and VCP, which are part of the proteasome system. The paper indicates that ataxin-3 might act as a proteasome-associated factor, which mediates the degradation of ubiquitinated proteins.
140. Burnett, B., Li, F. & Pittman, R. N. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 12, 3195-3205 (2003).
141. Gunawardena, S. et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40, 25-40 (2003). Ataxin-3 with short polyQ repeats in its C-terminal region is normally transported within axons of D. melanogaster larvae and accumulated at the neuromuscular junction. Larvae expressing ataxin-3 with expanded polyQ stretches show prominent axonal inclusions and axonal blockage, indicating that disruption of axonal transport could contribute to early neuropathology in polyQ diseases.
142. Yue, S., Serra, H. G., Zoghbi, H. Y. & Orr, H. T. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum. Mol. Genet. 10, 25-30 (2001).
143. Zhang, S., Xu, L., Lee, J. & Xu, T. Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. Cell 108, 45-56 (2002).
144. Li, F., Macfarlan, T., Pittman, R. N. & Chakravarti, D. Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J. Biol. Chem. 277, 45004-45012 (2002).
145. La Spada, A. R. et al. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31, 913-927 (2001).
146. Mariotti, C. et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60, 1676-1679 (2003).
147. DeKosky, S. T. & Marek, K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 302, 830-834 (2003).
148. Martin, J. H. Neuroanatomy: Text and Atlas 2nd edn (Appleton & Lange, Stamford, Connecticut, 1996).